<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More


Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More


Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More


Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More


Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More


Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More


Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More


Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More


Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More


Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More


Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Organoid Technology: A Reliable Tool for Drug Screening

It is well-known that drug attrition rates for anticancer agents are very high. In fact, only about 5% of compounds in preclinical development eventually becoming approved for clinical use. The need for more clinically relevant preclinical models has been identified as one of the areas that can reduce this attrition rate by enabling better decisions when selecting agents to advance to the clinic.

Hubrecht Organoid Technology (HUB) 3D in vitro tumor organoids faithfully recapitulate the phenotypic and genetic features of their original tumor, and these models are playing an increasingly important role in drug discovery, particularly in identifying anticancer agents with improved translational potential. In this blog post we explore how 3D organoid models for cancer drug screening are a reliable and predictive tool, compared to 2D cell lines.

3D In Vitro Organoids

3D in vitro organoids are powerful predictive tools being used to study normal developmental processes and mechanisms of disease. Briefly, 3D in vitro organoids are microscopic self-organizing 3D structures grown from adult stem cells, and these “mini-organs” recapitulate the key structural and functional properties of the original source. Optimized HUB protocols have been established to develop models from both normal and diseased tissue, including tumor tissue (see here for a more in depth discussion on HUB tumor organoids). Based on data from numerous studies (for example, see here and here), organoids represent the first clinically relevant 3D in vitro model to show the following:

  • Genomic and phenotypic stability in long-term culture and after cryopreservation
  • Enhanced clinical predictivity
  • Ease of scalability relative to in vivo models

In 2019, Crown Bioscience entered into a strategic partnership with HUB to become the exclusive provider of HUB technology for preclinical cancer drug development and validation.

Biobanks Enable "Clinical Trials in a Dish"

Patient Derived Organoids

Living organoid biobanks have been developed and house many solid tumor types (with matched healthy organoids). Crown Bioscience has developed OrganoidBase™, an extensive searchable biobank consisting of almost 350 tumor organoid models derived from its collection of PDX models (i.e., patient-derived xenograft organoids [PDXOs]) with information on histopathology, IC50, genomic, and transcriptomic analysis data associated with drug response, and an additional 200+ models from primary patient samples (i.e., patient-derived organoids [PDOs]).

These models have varied indications with multiple models derived from over 20 organ and tissue types. Cancer is a highly heterogenous disease that can differ greatly among patients with the same type of cancer (intertumor heterogeneity) and within each patient (intratumor heterogeneity). Developing effective drug candidates requires a thorough understanding of tumor heterogeneity in patient-relevant and predictive preclinical models that reflect cancer’s cellular and population-level diversity.

Biobanks capture patient population heterogeneity, support large-scale studies, and ensure availability for repeat studies. In short, biobanks bring clinical trials into the lab (referred to as “Clinical trials in a dish”) and allow researchers to identify predictive biomarkers of response (based on genomic profiling), combine drug strategies (e.g., multiple dose ratios, combination effects), and test therapeutic windows with healthy controls.

Benefits of 3D Organoids versus 2D Cell Line Cultures

Most high throughput drug screens are conducted using 2D cell lines, which are easy to establish and manipulate and are great for providing quick results for early-stage decisions. Although the physiological relevance of these cultures is not ideal, they have made significant contributions to cancer biology, and they are still very valuable when it comes to target validation and for more fundamental biological questions like defining cell signaling pathways. However, these models are suboptimal when it comes to informing about clinical response.

Increasingly, 3D in vitro organoid models are being used to bridge between traditional 2D cell lines and in vivo models. As compared to 2D cell lines, 3D organoids have a structure that promotes relevant cell–cell interactions and cell–matrix connections, possess differential areas of nutrient supply, concentration gradients of oxygen, and exposure to different environmental stressors. Together, these complex interactions and features influence a variety of cellular processes, including proliferation, drug response, signaling, differentiation, and survival. However, as compared to in vivo models, 3D organoids still lack in some of the physiologically relevant conditions provided by in vivo models.

Like 2D cell lines, 3D organoids are amenable to large-scale drug screens, and relative to in vivo models, they are more cost efficient to develop and maintain over the long term and allow for earlier decision-making instead of waiting for late-stage in vivo model data. Furthermore, since organoids preserve many of the key features of the original tumor, matched in vivo models can be generated that provide a seamless transition from in vitro studies to animal-based validation studies.

Flexible Setup for Drug Screening

Predictive 3D organoid models can be used in typical oncology-relevant in vitro drug screening assays, including:

  • High-throughput screens: Tumor organoids can be grown in 384-well plates for large-scale library screens, and to evaluate efficacy, toxicity, and drug combination effects. Researchers can leverage multiple organoid models, such as those derived from matched healthy tissue, different tumor types, and/or different genetic backgrounds. Engineering technologies (e.g., CRISPR, transduction) can also be used to generate models with specific features such as fluorescent labelling.

  • Co-cultures for immuno-therapy applications: This is a growing application of interest whereby novel immunotherapies can be tested in vitro using co-cultures of tumor organoids with various human immune cell types, including TILs, CAR-T or specific tumor microenvironment (TME) components.

Like traditional high-throughput screens with 2D cell lines, 3D organoids are adaptable to standard in vitro assays such as IC50 measurements and luminescent cell viability (e.g., CTG) readouts for cell viability. Furthermore, pairing patient-relevant 3D in vitro tumor organoids with innovative High Content Imaging (HCI) and Analysis (HCA) platforms can generate extremely detailed cellular physiology profiles of complex cellular systems, including multicellular structures from organoids and co-cultures, such as co-culturing tumor organoids with immune cells for immunotherapy efficacy studies noted above. This powerful pairing significantly expands the amount of information obtained from cellular assays as compared to fixed endpoint assays such as CTG) or nuclei count.

Deeper insights into the mechanism of a specific compound are obtained using HCI and phenotypic and morphological measurements that can be made include:

  • Organoid and nucleus count, size, volume, shape
  • Necrosis and apoptosis markers
  • Epithelium formation and thickness
  • Polarity and swelling
  • Internalization
  • Cell cycle
  • Therapy/target localization
  • IC50, area under-the-curve (AUC)


Cancer drug discovery and development is a costly and risky endeavor. Although simple 2D cell line cultures remain valuable in drug discovery, there is increasing interest in clinically relevant 3D organoid models that offer the scalability of 2D cell lines and the predictivity of in vivo models. 3D organoid models for cancer drug screening are a reliable and predictive tool that faithfully recapitulate the genomic, morphological, and pathophysiological characteristics of the original tumor. They are genetically and phenotypically stable even after long-term culturing and cryopreservation, and they are amenable to traditional in vitro drug screening assays and co-cultures for immuno-therapy applications.

Visit Crown Bioscience’s Organoids for Oncology Drug Development site to learn more about how help researchers advance their drug discovery and development programs.

Related Posts